American biotechnology company Novavax has said that its Covid-19 vaccine has got emergency use authorisation for children in 12-17 years age group by India's drug regulator.
The company has claimed that its vaccine produced an immune response in the same age group in a mid- to late-stage study involving 460 Indian adolescents.
Last month Novavax had said its vaccine was 80% effective against Covid-19 in a late-stage trial testing the shot in 2,247 children aged 12 to 17 years.
The vaccine is manufactured in India by Serum Institute of India under the name of Covovax
Also watch: Covovax Explained: Adding another weapon to India's Covid arsenal
Covovax is the fourth Covid-19 vaccine to be authorised for adolescents aged 12 years and older in India after Biological E's Corbevax, Zydus Cadila's ZyCoV-D and Bharat Biotech's Covaxin.